FDA 483 - Qilu Pharmaceutical (Hainan) Co. Ltd. - November 06, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Qilu Pharmaceutical (Hainan) Co., Ltd., a sterile drug manufacturer, revealed multiple significant deficiencies. These included failures in following written procedures for visual inspection of in-process materials, inadequate investigations into unexplained discrepancies, and a lack of established or followed procedures to prevent microbiological contamination. Additionally, the firm failed to thoroughly review unexplained discrepancies and ensure the accuracy of computer system input and output, particularly concerning audit trails for filter integrity testing instruments.
ID · 723eae93-3a14-4608-bbf6-fb6e3f0a7637